Terug
80
18
Ook genoteerd als
ALPMY
OTC
Dagbereik
€ 15,80
€ 16,80
52-Weeksbereik
€ 8,40
€ 17,39
Volume
100
50D / 200D Gem.
€ 15,05
/
€ 12,11
Vorige Slotkoers
€ 16,15
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,6 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 3,3 | 3,7 |
| Net Margin % | 2,7 | 3,8 |
| Rev Growth 5Y % | 11,2 | 10,0 |
| D/E | 0,6 | 0,2 |
Belangrijkste Punten
Revenue grew 11,23% annually over 5 years — strong growth
Earnings grew 197,72% over the past year
ROE of 3,26% is below average
Generating 137,18B in free cash flow
P/E of 0,59 — trading at a low valuation
PEG of 0,26 suggests growth is underpriced
Groei
Revenue Growth (5Y)
11,23%
Revenue (1Y)19,25%
Earnings (1Y)197,72%
FCF Growth (3Y)-24,27%
Kwaliteit
Return on Equity
3,26%
ROIC1,31%
Net Margin2,65%
Op. Margin2,15%
Veiligheid
Debt / Equity
0,55
Current Ratio1,13
Interest Coverage2,32
Waardering
P/E Ratio
0,59
P/B Ratio0,02
EV/EBITDA16,40
Dividend Yield0,05%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,25% | Revenue Growth (3Y) | 12,22% |
| Earnings Growth (1Y) | 197,72% | Earnings Growth (3Y) | -28,30% |
| Revenue Growth (5Y) | 11,23% | Earnings Growth (5Y) | -19,46% |
| Profitability | |||
| Revenue (TTM) | 1,91T | Net Income (TTM) | 50,75B |
| ROE | 3,26% | ROA | 1,52% |
| Gross Margin | 81,74% | Operating Margin | 2,15% |
| Net Margin | 2,65% | Free Cash Flow (TTM) | 137,18B |
| ROIC | 1,31% | FCF Growth (3Y) | -24,27% |
| Safety | |||
| Debt / Equity | 0,55 | Current Ratio | 1,13 |
| Interest Coverage | 2,32 | Dividend Yield | 0,05% |
| Valuation | |||
| P/E Ratio | 0,59 | P/B Ratio | 0,02 |
| P/S Ratio | 0,02 | PEG Ratio | 0,26 |
| EV/EBITDA | 16,40 | Dividend Yield | 0,05% |
| Market Cap | 30,10B | Enterprise Value | 673,15B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,91T | 1,60T | 1,52T | 1,30T | 1,25T |
| Net Income | 50,75B | 17,05B | 98,71B | 124,09B | 120,59B |
| EPS (Diluted) | 28,24 | 9,47 | 54,09 | 67,05 | 64,90 |
| Gross Profit | 1,56T | 1,31T | 1,23T | 1,04T | 1,00T |
| Operating Income | 41,04B | 25,52B | 133,03B | 220,02B | 136,05B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3,34T | 3,57T | 2,46T | 2,33T | 2,27T |
| Total Liabilities | 1,83T | 1,97T | 948,56B | 872,09B | 887,51B |
| Shareholders' Equity | 1,51T | 1,60T | 1,51T | 1,46T | 1,39T |
| Total Debt | 831,43B | 1,01T | 200,01B | 212,74B | 278,26B |
| Cash & Equivalents | 188,37B | 335,69B | 376,84B | 315,99B | 326,13B |
| Current Assets | 1,20T | 1,19T | 1,05T | 923,35B | 872,59B |
| Current Liabilities | 1,06T | 1,29T | 726,03B | 687,41B | 592,37B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#33 of 1052
#478 of 618
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026